RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Brain Delivery of Biomimetic Phosphorus Dendrimer/Antibody Nanocomplexes for Enhanced Glioma Immunotherapy via Immune Modulation of T Cells and Natural Killer Cells.
Brain Delivery of Biomimetic Phosphorus Dendrimer/Antibody Nanocomplexes for Enhanced Glioma Immunotherapy via Immune Modulation of T Cells and Natural Killer Cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
完全调动多种免疫细胞的活性对于实现理想的肿瘤免疫治疗效果至关重要,但仍具有挑战性。在此,我们报道了一种基于磷树状大分子(称为AK128)/程序性细胞死亡蛋白1抗体(aPD1)纳米复合物(NCs)的纳米药物制剂,该制剂用M1型巨噬细胞膜(M1m)伪装,用于增强原位胶质瘤的免疫治疗。构建的AK128-aPD1@M1m NCs平均粒径为160.3 nm,具有良好的稳定性和细胞相容性。凭借修饰的M1m具有4和1整合素,NCs能够穿透血脑屏障,将具有内在免疫调节活性的AK128和aPD1共同递送至原位胶质瘤,并具有延长的血液循环时间。
我们发现,磷树状大分子AK128能够促进外周血单核细胞中自然杀伤(NK)细胞增殖,而递送的aPD1能够实现免疫检查点阻断(ICB),从而恢复细胞毒性T细胞和NK细胞,进而促进肿瘤细胞凋亡,同时大幅降低调节性T细胞的肿瘤分布,以改善胶质瘤免疫治疗。所开发的纳米药物制剂组成简单,通过利用纳米载体的免疫调节活性和抗体介导的ICB治疗,实现了对免疫细胞的多重调控,为癌症免疫治疗提供了一种有效策略。
Fully mobilizing the activities of multiple immune cells is crucial to achieve the desired tumor immunotherapeutic efficacy yet still remains challenging.
Herein, we report a nanomedicine formulation based on phosphorus dendrimer (termed AK128)/programmed cell death protein 1 antibody (aPD1) nanocomplexes (NCs) that are camouflaged with M1-type macrophage cell membranes (M1m) for enhanced immunotherapy of orthotopic glioma. The constructed AK128-aPD1@M1m NCs with a mean particle size of 160.
3 nm possess good stability and cytocompatibility. By virtue of the decorated M1m having 4 and 1 integrins, the NCs are able to penetrate the blood-brain barrier to codeliver both AK128 with intrinsic immunomodulatory activity and aPD1 to the orthotopic glioma with prolonged blood circulation time.
We show that the phosphorus dendrimer AK128 can boost natural killer (NK) cell proliferation in peripheral blood mononuclear cells, while the delivered aPD1 enables immune checkpoint blockade (ICB) to restore the cytotoxic T cells and NK cells, thus promoting tumor cell apoptosis and simultaneously decreasing the tumor distribution of regulatory T cells vastly for improved glioma immunotherapy.
The developed nanomedicine formulation with a simple composition achieves multiple modulations of immune cells by utilizing the immunomodulatory activity of nanocarrier and antibody-mediated ICB therapy, providing an effective strategy for cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。